Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Phase 1 Completed 73 enrolled Calypso Biotech BV

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.

Timeline

Start: 2020-09-28
Primary completion: 2024-04-02
Completion: 2024-04-02

Publications

Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CALY-002	Monoclonal antibody	—	Intravenous

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Summary

Timeline

Publications

Drugs

Indications